What else is being developed in this class of drugs similar to Mounjaro?

By Gwynne Sullivan, Amy Nowacoski · last reviewed May 9, 2026

Adapted from the Mounjaro for Diabetes FAQ with permission from the contributing authors.

Triple Agonists: https://blog.profil.com/blog/new-strategies-for-the-treatment-of-obesity-and-metabolic-dysfunctions

Dorzagliatin: Drug That Can “Cure” Diabetes https://biopharma.media/dorzagliatin-drug-that-can-cure-diabetes-2246/?fbclid=IwAR2STdc0HmldtvElK_6-qewFeTU_-Bd5tTfG3Q2cVLGzwRXyG0ME4BD8RUY

“Subcutaneous dosing every third day for 4 weeks in diabetic db/db mice of HISHS-30at 3 and 20 nmol/kg reduced HbA1c, body weight, triglycerides and glucagon levels robustly and markedly more than tirzepatide (Table) .Treatment with HISHS-30also led to an increase in serum and liver Fibroblast Growth Factor-21 (FGF-21) levels vs. tirzepatide. In conclusion, HISHS-30is a potent, long acting GIP/GLP-1/glucagon tri-receptor agonist, with higher effects on glucose homeostasis and metabolic biomarkers in diabetic mice than tirzepatide.” Effects of a Novel Long-Acting GIP/GLP-2/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism Diabetes, June 2022 https://diabetesjournals.org/diabetes/article/71/Supplement_1/744-P/145870/744-P-Effects-of-a-Novel-Long-Acting-GIP-GLP-1?searchresult=1

Eli Lilly’s Clinical Development Pipeline Medicines in Development with potential indications being investigated https://www.lilly.com/discovery/clinical-development-pipeline